Please wait a minute...
Reviews in Cardiovascular Medicine  2014, Vol. 15 Issue (4): 351-357     DOI: 10.3909/ricm0720
Review Previous articles | Next articles
Renal Denervation: Current Status and Future Applications
Sabas I. Gomez1, Pablo Urbandt2, Nirat Beohar2, Orlando Santana2
1 Division of Internal Medicine, Mount Sinai Heart Institute, Miami Beach, FL
2 Columbia University Division of Cardiology, Mount Sinai Heart Institute,Miami Beach, FL
Download:  PDF(219KB)  ( 109 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Despite the variety of antihypertensive agents that are available, resistant hypertension remains a significant clinical problem and a substantial economic burden. Over the past several years, renal sympathetic denervation has been introduced as a potential therapeutic option for this clinical problem. It is a catheter-based procedure that is showing promising results and appears to be associated with minimal or low risk. Thus far, two completed clinical trials have demonstrated excellent safety and encouraging outcomes. A review of these trials is the focus of this article, in addition to the analysis of ongoing studies, and the possible future applications of this technique.
Key words:  Resistant hypertension      Renal sympathetic denervation      Sympathetic overactivity      Cardiovascular disease     
Published:  30 December 2014     

Cite this article: 

Sabas I. Gomez, Pablo Urbandt, Nirat Beohar, Orlando Santana. Renal Denervation: Current Status and Future Applications. Reviews in Cardiovascular Medicine, 2014, 15(4): 351-357.

URL: 

https://rcm.imrpress.com/EN/10.3909/ricm0720     OR     https://rcm.imrpress.com/EN/Y2014/V15/I4/351

[1] Shanna J. Hardin, Mahavir Singh, Wintana Eyob, Jack C. Molnar, Rubens P. Homme, Akash K. George, Suresh C. Tyagi. Diet-induced chronic syndrome, metabolically transformed trimethylamine-N-oxide, and the cardiovascular functions[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 121-128.
[2] Wenyan Jiang, Mei Wang. New insights into the immunomodulatory role of exosomes in cardiovascular disease[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 153-160.
[3] Rudaynah A. Alali. A short review of proprotein convertase subtilisin/kexin type 9 inhibitors[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 1-8.
[4] Davide Bolignano, Giuseppe Coppolino. Renal nerve ablation for resistant hypertension: facts, fictions and future directions[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 9-18.
[5] Jennifer G. Robinson, Karol E. Watson. Identifying Patients for Nonstatin Therapy[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 1-8.
[6] Davide Bolignano, Anna Pisano, Graziella D’Arrigo. Pulmonary hypertension: a neglected risk condition in renal patients?[J]. Reviews in Cardiovascular Medicine, 2018, 19(4): 117-121.
[7] Davide Bolignano, Giuseppe Coppolino. Baroreflex stimulation for treating resistant hypertension: ready for the prime-time?[J]. Reviews in Cardiovascular Medicine, 2018, 19(3): 89-95.
[8] Peter A. McCullough, Aaron Y. Kluger, Kristen M. Tecson, Clay M. Barbin, Andy Y. Lee, Edgar V. Lerma, Zachary P. Rosol, Sivan L. Kluger, Janani Rangaswami. Inhibition of the Sodium–Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2[J]. Reviews in Cardiovascular Medicine, 2018, 19(2): 51-63.
[9] Alberto Palazzuoli, Helen Hashemi, Lauren C. Jameson, Peter A. McCullough. Hyperuricemia and Cardiovascular Disease[J]. Reviews in Cardiovascular Medicine, 2017, 18(4): 134-145.
[10] Claudio Ronco, Federico Ronco, Peter A. McCullough. A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine[J]. Reviews in Cardiovascular Medicine, 2017, 18(3): 93-99.
[11] Bashar Hannawi, Homam Ibrahim, Colin M. Barker. Renal Denervation: Past, Present, and Future[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 114-124.
[12] Boback Ziaeian, John Dinkler, Karol Watson. Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy International Trial[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 125-130.
[13] Norman E. Lepor, Dean D. Fouchia, Peter A. McCulloughsup. New Vistas for the Treatment of Obesity: Turning the Tide Against the Leading Cause of Morbidity and Cardiovascular Mortality in the Developed World[J]. Reviews in Cardiovascular Medicine, 2014, 15(S2): 1-21.
[14] Virginia A. Triant. Epidemiology of Coronary Heart Disease in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 1-8.
[15] Patrick W.G. Mallon. Impact of Nucleoside Reverse Transcriptase Inhibitors on Coronary Heart Disease[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 21-29.
No Suggested Reading articles found!